1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Prophylaxis Results Set Stage For Expanded Japan Xofluza Use

 
• By Ian Haydock

Shionogi’s novel single-dose flu drug shows promise in first Phase III results in post-exposure prevention, paving the way for a Japanese filing in this setting and potentially expanding already healthy sales.  

Influenza A H7N9
Xofluza Looks Good In Flu Prophylaxis • Source: Shutterstock

Shionogi & Co. Ltd.'s novel influenza drug Xofluza (baloxavir marboxil) has met its primary endpoint in a Phase III trial which looked at its ability to halt symptoms in people already exposed to the virus, setting the stage for a Japanese approval filing in this setting.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia